BH
Benjamin Halladay
Chief Financial Officer

Benjamin Halladay insider trades: Esperion Therapeutics (ESPR) stock sales

Chief Financial Officer, Esperion Therapeutics Last trade Jun 17, 2026 17 Form 4 filings
$78K
Sold, last 12 months
3 sales
$0
Bought, last 12 months
0 buys
11
Open-market trades
since 2024
2
Companies
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Benjamin reports to the SEC

Open-market buys and sales

11 trades reported on SEC Form 4, newest first

DateStockTypeValue
Jun 17, 2026ESPR↓ Sell$34K
Mar 17, 2026ESPR↓ Sell$17K
Dec 17, 2025ESPR↓ Sell$27K
Sep 17, 2025ESPR↓ Sell$20K
Jul 17, 2025ESPR↓ Sell$12
Jun 17, 2025ESPR↓ Sell$8K
Apr 17, 2025ESPR↓ Sell$8
Mar 18, 2025ESPR↓ Sell$5K
Feb 19, 2025ESPR↓ Sell$20
Jan 17, 2025ESPR↓ Sell$20
Dec 17, 2024ESPR↓ Sell$8K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other ESPR insiders

Open-market trades in the last 12 months

About Benjamin Halladay's insider trades

Benjamin Halladay is Chief Financial Officer at Esperion Therapeutics (ESPR). Since Dec 17, 2024, Benjamin has reported no open-market purchases and 11 sales worth $120K on SEC Form 4. In the last 12 months: 3 sales ($78K).

Their filings also include grants and awards (6 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ESPR insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.